Log in using OpenID

Global Recombinant Vaccines Market at a Rapid Pace Until 2025

Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector. These vaccines stimulate the immune system of an individual and provide immunity against various lethal disease.
Global Recombinant Vaccines Market Health
Improvement Aspects, Expert Reviews, Research
2017 to 2025
Global Recombinant Vaccines Market, By Product Type (Subunit Recombinant
Vaccines, Attenuated Recombinant Vaccines, Vector Recombinant Vaccines),
Disease Type (Infectious Disease, Cancer, Allergy), End User (Recombinant
Human Vaccines, Animal Recombinant Vaccines), and Geography - Insights,
Size, Share, Opportunity Analysis, and Industry Forecast till 2025
Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector.
These vaccines stimulate the immune system of an individual and provide immunity against various
lethal disease. These vaccines are safe and have less or no side-effects as compared to conventional
vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue.
Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth
disease, pneumonia and septicemia, and pox disease. The Global Recombinant Vaccines Market was
valued at US$ 830.2 million in 2016 and is expected to witness a robust CAGR of 6.0% during the
forecast period (2017 – 2025).
Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of
pathogenic microorganisms. There is increase in the demand for livestock products, which in turn has
increased growth of the animal recombinant vaccine segment and Europe dominates the animal
recombinant vaccines market as compared to other regions due to highly organized livestock and huge
demand of livestock product for the European population. According to Global Agriculture report, there
were around 315 million tons of meat produced worldwide in 2014 and expected to increase to 318.8
million tons in 2015.
Market Dynamics
The recent past has witnessed a steady rise in incidence of zoonotic and infectious diseases in humans
and animals as well, which lead to the increased research & developments for the innovation of new
and effective recombinant vaccines for the prevention of diseases. Government has also taken an
initiative to increase awareness regarding vaccination to prevent diseases in community. Manufacturing
companies have also started some beneficial programs to provide vaccination free of cost to poor
people, which creates a highly conducive environment for growth of the recombinant vaccines market
in near future.
Ask For a Sample Copy of This Business Report :
National Immunization Program by Queensland Government in Australia and Indradhanush
vaccination program in India works to provide vaccination among children throughout the nation.
Various organizations such as World Health Organization, World Bank, and United Nations Children’s
Funds has also taken and initiative to increase vaccination.
Increase in the incidence of zoonotic diseases and emerging technologies expected to support the
growth of recombinant vaccines market
There is a constant increase in diseases caused by bacteria or virus such as swine flu, malaria, HPV and
other diseases, which has raised the demand of vaccination and lead to the eradication of diseases such
as polio, and tetanus in few countries. Whit the development in technology there is development in
vaccines, which are more effective than conventional vaccines and does not lead to any side effect.
These vaccines are easy to administer in the body orally, intramuscular or intradermal. In the U.S. there
were around 212 million malaria cases and 429,000 deaths from malaria is reported in 2015. According
to Centers for Disease Control and Prevention report 2017, in the U.S. there were around 49.9% of the
children between the ages of 6 months to 17 years received an influenza vaccine.
Some major key players in the recombinant vaccines market include Merck & Co. Inc., Novartis AG,
Protein Science Corporation, GlaxoSmithKline Plc., Green Cross Corporation, Bayer AG, Sanofi S A,
Pfizer Inc., and Bharat Biotech.
Continuous investment in research & development for the development of new vaccines and
increased awareness and pet adoption are expected to fuel the growth of recombinant vaccines
There are various companies working on the development of vaccine for various disease, which have
affected human beings in short span of time such as Ebola, Zika, and H1N1 flu. The companies also
working for the development of cancer vaccines different type of cancer includes lung cancer, blood
cancer, skin cancer, bladder cancer, brain cancer, kidney cancer, prostate cancer, solid tumors cancer ,
breast cancer are the target area for recombinant vaccine development, which may expected to support
the growth of recombinant vaccine market in the near future.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
ravikiran303   documents Email
Health and Medicine
File Size
369 KB
Report inappropriate content